{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Acute GVHD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}],"title":"Extensive Chronic GVHD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"description":"Graft-vs-host disease (GVHD) can be mild, moderate or severe depending on the differences in tissue type between patient and donor. Its symptoms can include:\n\n* Rashes, which include burning and redness, that erupt on the palms or soles and may spread to the trunk and eventually to the entire body\n* Blistering, causing the exposed skin surface to flake off in severe cases\n* Nausea, vomiting, abdominal cramps, diarrhea and loss of appetite, which can indicate that the gastrointestinal (digestive) tract is affected\n* Jaundice, or a yellowing of the skin, which can indicate liver damage\n* Excessive dryness of the mouth and throat, leading to ulcers\n* Dryness of the lungs, vagina and other surfaces\n\nAcute GVHD - Can occur soon after the transplanted cells begin to appear in the recipient. Acute GVHD ranges from mild, moderate or severe, and can be life-threatening if its effects are not controlled.\n\nExtensive chronic GVHD - Usually occurs at about three months post-transplant.","groups":[{"description":"All patients received IV fludarabine 30 mg/m2/day on days -7 through -3; busulfan 6.4 mg/kg by continuous infusion over 48 hours on days -6 through -5 and tacrolimus from day -1. Throughout the study duration, 8 different GVHD regimens were investigated. In addition to tacrolimus, patients received combinations of 3 agents: methotrexate (5 mg/m2 D1, 3, 6), rabbit antithymocyte globulin (ATG, 3 mg/kg to- 6 mg/kg) or alemtuzumab (Campath, 30 mg to- 90 mg).","id":"OG000","title":"All Trial Participants"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 Months","title":"Graft-vs-host Disease at 6 Months Post-transplant","type":"SECONDARY","unitOfMeasure":"percentage of participants"}